【FINTEC 0150 交流专区】（前名 ASIABIO）

icy97

icy97 发表于 18-1-2013 12:38 AM

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ABT” OR “THE COMPANY”) - PROPOSED JOINT VENTURE BETWEEN ABT, NEXFUEL SDN BHD (“NEXFUEL”) AND HEXA BONANZA SDN BHD (“HEXA”) ON THE DEVELOPMENT OF HEXA’S BIOMASS COMPOST PELLETIZING BUSINESS USING OIL PALM TRUNK PEELED LUMBER MACHINE AND TECHNOLOGY SUPPLIED BY NEXFUEL (“JV PROJECT”)
We refer to section 2.6 of the Company’s announcement on the JV Project dated 17 January 2013 (hereinafter referred to as “JV Project Announcement”). We wish to clarify that the amount of balance of the deferred consideration payable to Liew Yeow Hooi and Chew Ean Nar by ABT, as disclosed in Section 2.6 of the JV Project Announcemnet being mutually waived off is amounting to RM3,250,000. This annoucement is dated 22 January 2013.

icy97

宜鼎機械與亞洲生物能源‧聯營生物科技業務

大馬  2013-03-13 11:25
（吉隆坡13日訊）宜鼎機械（AT,0072,創業板工業產品組）與亞洲生物能源（ASIABIO,0150,創業板貿服組）簽署合作協議，以合作供應將廚餘轉化成有機廢料的生物科技解決方案。

該公司發文告表示，根據協議，公司將負責製造和生產與維修堆肥機械（Composting Machine），以及取得有關當局對工程的審批，而亞洲生物能源則將負責提供將廚餘轉換成有機廢料的必要微生物解決方案和確認堆肥機械的設計。（星洲日報／財經）

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) - JOINT COLLABORATION AGREEMENT BETWEEN THE COMPANY AND AT SYSTEMIZATION BERHAD
The Board of Directors of Company is pleased to announce that the Company has on 11 March 2013, entered into a Joint Collaboration Agreement with AT Systemization Berhad (“AT”) to set out of the terms of their intention to collaborate in the supply biotechnology solutions to schools, government bodies, military bases, national service camps, colleges and universities in Malaysia to convert food waste to organic fertilizer (hereinafter referred to as“the Project”). AT, which is listed on Bursa Securities, is involved in the fabrication of industrial and engineering parts and design and manufacture of industrial automation system and machinery.  AT, via its subsidiary AT Engineering Solution Sdn Bhd, has submitted a proposal to the Education Ministry of Malaysia for the implementation of a food waste conversion system using biotechnology at schools in Malaysia. The intention of the parties under the Joint Collaboration Agreement is to work together wherein AT shall be responsible for the fabrication and manufacture and maintenance of the composting machineries as well as secure the approval of the relevant authorities for the Project and Asiabio, via its wholly owned subsidiary company, Hexa Bonanza Sdn Bhd, shall be responsible for the provision of the microbial solutions necessary for the conversion of the food waste into organic fertilizer as well as identification of the composting machinery design for the fabrication by AT. The Joint Collaboration Agreement shall take effect on the date of its execution and shall continue to be of effect until the execution of a definitive agreement, which the parties agree to execute within three (3) months from the date of the Joint Collaboration Agreement. This announcement is dated 12 March 2013.

icy97

icy97 发表于 11-12-2012 09:41 AM
亚洲生化卖Platinum Nanochem 1.56% 换英国Biofutures 1.08%

财经新闻 财经  2012-12-12 11:48

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR “COMPANY”) PROPOSED DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ORDINARY SHARES, IN PLATINUM NANOCHEM SDN BHD (FORMERLY KNOWN AS PLATINUM ENERGY SDN BHD) TO BIOFUTURES INTERNATIONAL PLC (“BIP”) (“PROPOSAL”)
Reference is made to the Company’s announcement on 11 December 2012 and 17 December 2012 on the proposed disposal of 1,143,434 ordinary shares of RM1.00 each in Platinum Nanochem Sdn Bhd (“PNSB”) to Biofutures International PLC (“BIP”) (“Proposal”). We have on 26 March 2013, received notification from PNSB that the shareholders of BIP have vide an Extraordingary General Meeting held on 25 March 2013 approved the proposed acquisition of PNSB, with a revision to the number of shares to be issued as consideration. Pursuant thereto, the vendors of PNSB have executed supplemental documents wherein Asia Bioenergy Technologies Berhad will receive 21,018,714 new ordinary shares of BIP (“Said Shares”) which Total Platinum Holdings Sdn Bhd, the main promoter of PNSB having a 12-month option to acquire the Said Shares at a price of ￡0.06 per share (“Share Price”) i.e. a total consideration of ￡1,261,123 (or RM 5,873,049 based on an exchange rate of ￡1:RM4.657). The Share Price of ￡0.06 per share represents a discount of 9.4% over the last five (5) days weighted average market price of BIP shares up to 25 March 2013 of approximately ￡0.06565 per share, the last practicable date prior to the date of this announcement. In view of the above, the Proposal will result in a revised gain on disposal of PNSB of RM5,683,654 to AsiaBio Group. The highest percentage ratio applicable to the Amended Agreement and Option Agreement pursuant to Rule 10.02(g) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad is 24.05%. All other salient features of the Proposal remain the same per the original announcement. The Proposal have also been completed on 26 March 2013 with the re-admission of BIP under its new name of Graphene NanoChem Plc. Copies of the Amended Agreement and Option Agreement are available for inspection at the registered office of ABT during normal business hours from Monday to Friday (except public holidays) at B-11-10, Megan Avenue II, Jalan Yap Kwan Seng, 50450 Kuala Lumpur for a period of 3 months from the date of this announcement. This announcement is dated 26 March 2013.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/01/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/01/2013	31/01/2012	31/01/2013	31/01/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	946	398	2,313	5,517
2	Profit/(loss) before tax	-2,090	-18,666	-4,317	-18,351
3	Profit/(loss) for the period	-2,161	-18,701	-4,403	-18,443
4	Profit/(loss) attributable to ordinary equity holders of the parent	-2,161	-18,601	-4,394	-19,950
5	Basic earnings/(loss) per share (Subunit)	-0.57	-5.08	-1.15	-5.45
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0531		0.0644

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIABIOENERGY TECHNOLOGIES BERHAD ("ASIABIO OR THE "COMPANY") ACQUISITION OF REMAINING SHARES IN SUBSIDIARY
1. Introduction We wish to announce that Asiabio has today acquired the remaining 20,000 ordinary shares of RM1.00 each representing 20.0% of the issued and paid-up capital of Eco-Sponge Sdn Bhd (“Eco-Sponge”), an existing subsidiary of Asiabio, from the vendor, Tan KiatPoh, for a cash consideration amount of RM2.00 only (“Acquisition”).  With the acquisition of the remaining shares, Asiabio has increased its shareholding in Eco-Sponge to 100%.   2. Information on Eco-Sponge Eco-Sponge was incorporated in Malaysia under the Companies Act 1965 on 21 August 2007 and is involved in the manufacturing of absorbent filtration compound for the biodiesel industry. It is presently inactive. 3. Purchase Consideration The purchase consideration was arrived at after taking into consideration the inactive status of the company as well as its audited net liabilities of RM24,275 and net losses of RM16,845 for the financial year ended 31 January 2012. 4. Rationale of the Acquisition The Acquisition will give Asiabio full control of the company and its business, the direction and prospect of which will be determined later. 5. Financial Effects The Acquisition is not expected to have any material effect on the earnings per share of Asiabio Group for the financial year ending 31 January 2014, share capital, major shareholders’ shareholdings, net assets per share, gearing and dividend policy of Asiabio Group.  Nonetheless, barring any unforeseen circumstances, the Acquisition is expected to contribute positively to the future earnings of the Company upon successful implementation of the business turnaround of Eco-Sponge. There are no liabilities, including contingent liabilities or guarantees,expected to be assumed by Asiabioor the vendor from the Acquisition. 6. Percentage Ratio The highest percentage ratio applicable to the Acquisition is negligible. 7. Directors’ and Major Shareholders’ Interest None of the Directors, substantial shareholders and/or persons connected with the Directors and/or substantial shareholders of Asiabio has any interest, direct or indirect, in the Acquisition. 8. Statement by Directors The Board of Directors of Asiabio is of the opinion that the Acquisition is in the best interest of Asiabio. 9. Approvals The Acquisition is not subject to the approval of shareholders and regulatory authorities. This announcement is dated 28 March 2013.

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Reply to query
Reply to Bursa Malaysia's Query Letter - Reference ID	NS-130401-42025
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD ("ASIABIO" OR "COMPANY") PROPOSED DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ORDINARY SHARES, IN PLATINUM NANOCHEM SDN BHD ("PNSB") (FORMERLY KNOWN AS PLATINUM ENERGY SDN BHD) TO BIOFUTURES INTERNATIONAL PLC ("BIP") ("PROPOSAL")
We refer to the query letter from Bursa Malaysia Securities Berhad dated 1 April 2013. In reply to the query, we wish to clarify that pursuant to the supplemental documents between the vendors of Platinum NanoChem Sdn Bhd (“PNSB”) and Biofutures International Plc (“BIP”) as announced on 26 March 2013, Asiabio will receive an increase in the number of consideration shares of BIP, totaling 21,018,714 new ordinary shares ("Consideration Shares") in exchange for the 1,143,434 ordinary shares in PNSB.  The issue price of the consideration shares of BIP remains unchanged at ￡0.07 per share as per the announcement dated 11 December 2012, resulting in a deemed consideration of ￡1,471,310 or RM6,851,890 based on the exchange rate of ￡1:RM4.657. However, under the revised arrangement, Asiabio also executed an option agreement with Total Platinum Holdings Sdn Bhd ("TPH"), whereby an option is given to TPH to acquire the said Consideration Shares at ￡0.06 per share i.e. a total consideration of ￡1,261,123 (or RM5,873,049) for a six (6) months period commencing from the expiry of the 12-month lock-in period.  Upon expiry of the option period, if Asiabio intends to sell the Consideration Shares, Asiabio shall offer to TPH the first right of refusal to purchase at ￡0.06 per share, exercisable within six (6) months from the expiry of the option period. In view of the option agreement, and in compliance with requirements of Rule 10.03 (5) of Chapter 10 of the ACE Market Listing Requirements, the consideration sum of RM5.8 million calculated based on the option price of ￡0.06 per share was disclosed. This announcement is dated 2 April 2013.

icy97

icy97 发表于 27-3-2013 01:01 AM

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD ("ASIABIO" OR "THE COMPANY") DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ORDINARY SHARES, IN PLATINUM NANOCHEM SDN BHD (FORMERLY KNOWN AS PLATINUM ENERGY SDN BHD) TO BIOFUTURES INTERNATIONAL PLC (“BIP”) (“DISPOSAL”)
We refer to our announcement dated 26 March 2013. We wish to announce on behalf of the Board of Directors of the Company that Bursa Malaysia Securities Berhad ("Bursa Malaysia") has informed that since Asiabio has received a total of 21,018,714 new ordinary shares in Biofutures International PLC (“BIP”) issued at a price of ￡0.07 per BIP share, the deemed consideration for the disposal of 1,143,434 ordinary shares of RM1.00 each, representing 1.56% of the total ordinary shares, in Platinum NanoChem Sdn Bhd (“Disposal”) should be taken as ￡1,471,310 (or RM6,851,890 based on the exchange rate of ￡1:RM4.657). The option agreement with Total Platinum Holdings Sdn Bhd (“TPHSB”) whereby an option has been granted to TPHSB to acquire the Consideration Shares at ￡0.06 per share is to be regarded as a separate and distinct transaction. Based on the above, the highest applicable percentage ratio for the Disposal is 27.8%.  Therefore, shareholders’ approval is required for the Disposal. In connection with the above, we wish to announce that the Company has on even date written in to Bursa Malaysia to seek for a waiver on the requirement for the shareholders’ approval and sponsor/advisor for proposals involving the disposal of assets in part or as whole due to a listing exercise or reverse takeovers, inclusive of the Disposal, failing which the right to ratify the transaction at an Extraordinary General Meeting to be convened. The Company shall make an appropriate announcement on the decision taken by Bursa Malaysia upon receiving the outcome. This announcement is dated 8 April 2013.

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Particulars of substantial Securities Holder

Name	Looi Kem Loong
Address	No. 48 Jalan Hujan Bubuk 3 Overseas Union Garden Bt 5, Jalan Klang Lama 58200 Kuala Lumpur
NRIC/Passport No/Company No.	751224-07-5659
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	Acritaz Holdings Sdn Bhd A-3A-09 Oasis Ara Damansara 2 Jalan PJU 1A/7A 47301 Petaling Jaya Selangor

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Date of change	No of securities	Price Transacted (RM)
Disposed	30/04/2013	50,000,000	0.070

Circumstances by reason of which change has occurred	Disposal of shares
Nature of interest	Indirect
Direct (units)	733
Direct (%)	0
Indirect/deemed interest (units)	30,704,333
Indirect/deemed interest (%)	8.04
Total no of securities after change	30,705,066
Date of notice	03/05/2013

icy97

福泰中国投资控股 晋亚洲生化大股东

财经新闻 财经  2013-05-11 10:50
（吉隆坡10日讯）福泰中国投资控股有限公司（CPE）以350万令吉收购亚洲生化（AsiaBio，0150，创业板）13%持股权，晋身为大股东。

亚洲生化向马交所报备，福泰中国投资控股透过旗下位于香港的CPE GrowthCapital有限公司在4月30日收购亚洲生化5000万股票，持股比例相等于13%。

虽亚洲生化未透露交易价，但根据福泰中国投资本月8日发布在官网的文告，公司以每股7仙的价格收购亚洲生化13.08%股权，总值350万令吉。

大马市场对福泰中国投资控股并不陌生，较早前，公司购入巴迪玛斯（Patimas，7042，主板科技股）近5.1%股权，晋身大股东行列。

福泰中国投资执行主席约翰克拉夫指出，公司一直致力在亚洲寻找投资机会，特别是金融服务或是TMT行业（指融合高科技、传媒、电信）领域，而亚洲生化核心业务与资讯科技和生物科技相关。[南洋网财经]

Name	CPE GROWTH CAPITAL LIMITED
Address	16/F CHUNG NAM BUILDING 1 LOCKHART ROAD, WANCHAI HONG KONG
NRIC/Passport No/Company No.	1709460
Nationality/Country of incorporation	BRITISH VIRGIN ISLANDS
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	CPE GROWTH CAPITAL LIMITED 16/F CHUNG NAM BUILDING 1 LOCKHART ROAD, WANCHAI HONG KONG

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	30/04/2013
No of securities	50,000,000
Circumstances by reason of which Securities Holder has interest	Portfolio investment
Nature of interest	Direct
Price Transacted ($$)
Total no of securities after change
Direct (units)	50,000,000
Direct (%)	13.08
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	07/05/2013

chinesesp

icy97 发表于 11-5-2013 05:20 AM
福泰中国投资控股 晋亚洲生化大股东

财经新闻 财经  2013-05-11 10:50

@williamnkk81
如何看待这公司？？早前CPE GrowthCapital购入巴迪玛斯（Patimas，7042，主板科技股）近5.1%股权后Patimas股价好像去参加中国星跳跃酱呢。。。十米高台往下跳

icy97

亚洲生化与OVG及CPM签约 合作推出互动媒体平台

财经新闻 财经  2013-06-12 11:20
（吉隆坡11日讯）亚洲生化（AsiaBio，0150，创业板）宣布，与Omni Ventures Global有限公司（简称OVG）和Hunan China Post Media有限公司（简称CPM）签署意向备忘录，合作推出互动媒体平台。

亚洲生化向马交所报备，昨天与OVG和CPM签署上述备忘录，共同草拟合作推出互动媒体平台的合约内容。

CPM筹资3000万

文告指出，CPM为中国邮政的间接联营子公司，拥有在全中国邮局分局内，安装、持有和营运电子广告网络平台的特权，为期10年。

截至目前，CPM已经在中国部分地区的3000家邮局分局内，安装被动式的电子网络平台，并有意提升为互动电子网络平台，以提供额外服务。

CPM就此表示，有意寻找海外合作伙伴进行上述拓展计划，并筹资1000万美元（约3000万令吉）将该服务推向尚未进军的区域。[中国报财经]

Type	Announcement
Subject	OTHERS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) MEMORANDUM OF INTENT BETWEEN THE COMPANY, OMNI VENTURES GLOBAL LTD AND HUNAN CHINA POST MEDIA LIMITED (“CPM”) FOR COLLABORATION AND INVESTMENT INTO CPM
The Board of Directors of the Company wishes to announce that the Company has on 10 June 2013, entered into a Memorandum of Intent with Omni Ventures Global Ltd (“OVG”) and Hunan China Post Media Limited (“CPM”) to set out of the terms of their collaboration in the launch of interactive media platform using CPM’s rights within the perimeters of the memorandum (hereinafter referred to as “the Project”). OVG is an investment company incorporated in British Virgin Island and specializes in marketing and promotions in Hong Kong and China whereas CPM is an indirect associated company of China Post, the national post agency in China. CPM holds the rights to install, own and operate in-store digital network that provides point of sale advertising platform at China Post’s outlets throughout China for ten (10) years (“Media Rights”) and has to date rolled out installation at some 3,000 outlets in certain districts in China. CPM also intends to rollout interactive kiosks operate along side with the existing passive in-store digital media platform that provides video advertising services, the expansion is to enable an interactive media platform that is able to provide additional services (“Expansion Plans”). CPM intends to restructure via a holding company (“HoldCo”) to be incorporated offshore with the intention to raise further funding of an estimated sum of USD10 million for its expansion into other districts in China, with an ultimate intention of seeking a listing on a recognized stock exchange. The salient terms of the Memorandum of Intent are as follows:- • OVG shall provide its expertise, contacts and know-how in the Expansion Plans. • OVG and AsiaBio to secure the required funding of USD10 million either by way of direct investment or acquisition from certain shareholders or other means mutually agreeable. • CPM shall allow Omni and/or AsiaBio access to any material or parties necessary to conduct an operational and financial due-diligence. • CPM shall detail out the proposed utilization of the funds required estimated at USD10 million. • Via a legal due diligence to be performed, CPM shall prove to OVG and AsiaBio that their existing Media Rights also cover China Post’s kiosks outlets and installation of the interactive platform as aforementioned, unless otherwise waived mutually. The Memorandum of Intent shall take effect on the date of its execution and shall be valid for a period of six (6) months.  In the initial three (3) months, the parties shall negotiate with each other on an exclusive basis and with first right for the balance three (3) months, within which the parties shall endeavor to execute a definitive investment and shareholders’ agreement based on this Memorandum of Intent. This announcement is dated 10 June 2013.

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”)a • PRIVATE PLACEMENT
We refer to the Company’s previous announcements in relation to the private placement of up to ten percent (10%) of the issued and paid-up share capital of AsiaBio (“Private Placement”). For consistency purposes, the abbreviations and definitions used throughout this announcement are the same as those previously defined in the Company’s announcement dated 28 November 2012.    On behalf of the Board of Directors of AsiaBio, KAF is pleased to announce that the Company has fixed the issue price for the Private Placement comprising 38,200,000 Placement Shares at RM0.10 per Placement Share. The said issue price of RM0.10 per Placement Share represents a discount of approximately 7.15% from the five (5)-day weighted average market price of AsiaBio Shares up to and including 7 June 2013 of approximately RM0.1077 per AsiaBio Share as traded on Bursa Securities.    This announcement is dated 10 June 2013.

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”)
PROPOSED DISPOSAL BY ASIABIO OF 19.99% EQUITY INTEREST OF OVAL ALLIANCE SDN BHD (“OVAL”) COMPRISING 500,000 ORDINARY SHARES OF RM1.00 EACH FOR A CASH CONSIDERATION OF RM550,000 (“PROPOSED DISPOSAL”) This announcement is dated 12 June 2013.

Attachments ABTB-Announcement dated 12.6.2013 (Proposed Disposal of Oval).pdf

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

1. Details of Corporate Proposal
Whether the corporate proposal involves the issuance of new type and new class of securities?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	PRIVATE PLACEMENT OF UP TO 38,200,000 NEW ORDINARY SHARES OF RM0.10 EACH IN ASIABIO REPRESENTING UP TO 10% OF THE ISSUED AND PAID-UP SHARE CAPITAL OF ASIABIO
No. of shares issued under this corporate proposal	38,200,000
Issue price per share ($$)	MYR 0.100
Par Value ($$)	MYR 0.100
Latest issued and paid up share capital after the above corporate proposal in the following
Units	420,200,000
Currency	MYR 42,020,000.000
Listing Date	19/06/2013

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/04/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/04/2013	30/04/2012	30/04/2013	30/04/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	52	303	52	303
2	Profit/(loss) before tax	2,359	9	2,359	9
3	Profit/(loss) for the period	2,359	9	2,359	9
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,385	12	2,385	12
5	Basic earnings/(loss) per share (Subunit)	0.62	0.00	0.62	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0594		0.0531

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Particulars of Substantial Securities Holder

Name	The Goldman Sachs Group, Inc.
Address	Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, United States of America
NRIC/Passport No/Company No.	2923466
Nationality/Country of incorporation	United States of America
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	Goldman Sachs International ("GSI") Peterborough Court, 133 Fleet Street, London EC4A 2BB, United Kingdom

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	14/06/2013
No of securities	20,638,000
Circumstances by reason of which Securities Holder has interest	Indirect interest through open market acquisition of shares of Asia Bioenergy Technologies Berhad by GSI. GSI is a subsidiary of Goldman Sachs Holdings (U.K.), which is in turn a subsidiary of Goldman Sachs (UK) L.L.C. The Goldman Sachs Group, Inc. is the direct holding company of Goldman Sachs (UK) L.L.C. and the ultimate holding company of the other aforementioned entities.
Nature of interest	Indirect interest
Price Transacted ($$)
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	20,638,000
Indirect/deemed interest (%)	5.4
Date of notice	21/06/2013

icy97

icy97 发表于 9-4-2013 02:23 AM

Biofutures 交易额变动 亚洲生化须股东批准

财经新闻 财经  2013-07-14 12:18
（吉隆坡13日讯）大马交易所拒绝亚洲生化（AsiaBio，0150，创业板）的申请，后者必须尽速针对与英国上市公司Biofutures国际股权交易数额变动一事，寻求股东批准。

亚洲生化去年杪献议与多名卖家透过换股方式，脱售Platinum Nanochem私人股权予Biofutures国际，而亚洲生化可以126万1123英镑（587万3049令吉）或每股0.06英镑的代价，换取Biofutures国际1.05%股权。

不过，马交所在今年4月时发信予亚洲生化，称该公司是以每股0.07英镑的价格，获得Biofutures国际的2101万8714股新普通股，认为亚洲生化脱售Platium Nanochem股权的金额，实则为147万1310英镑（685万1890令吉）。

有鉴于此，亚洲生化当时表示，将向马交所申请豁免针对交易数额的改变，而寻求股东批准的步骤。[南洋网财经]

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD ("ASIABIO" OR THE "COMPANY") APPLICATION FOR A WAIVER FROM COMPLIANCE WITH PART D OF CHAPTER 10 OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") FOR THE ACE MARKET IN RESPECT OF PROPOSALS TO DISPOSE OFF ASSETS THAT ARE PART OR WHOLE OF A LISTING EXERCISE ("APPLICATION")
We refer to our announcement on 8 April 2013. We wish to announce that the Company has received a letter from Bursa Malaysia Berhad dated 10 July 2013 on 12 July 2013. Bursa Securities had considered the Application and rejected the Application. However, Bursa Securities requires the Company to seek shareholders’ ratification for the revised consideration of the proposed disposal of 1,143,434 ordinary shares of RM1.00 each, representing 1.56% of the total ordinary shares, in Platinum Nanochem Sdn Bhd (formerly known as Platinum Energy Sdn Bhd) to Biofutures International PLC ("BIP") wherein the Company shall receive 21,018,714 new BIP shares i.e. a total consideration of ￡1,471,310 or RM6,851,890 instead as soon as possible. The Board of Directors will deliberate on the above matter and shall keep the shareholders informed of any development. This announcement is dated 12 July 2013.

icy97

中國私募基金看好東南亞潛能

大馬  2013-07-27 10:45
（吉隆坡26日訊）較早收購亞洲生物能源（ASIABIO,0150,創業板貿服組）13.08%股權的中國私募基金控股指出，他們看好東南亞區域發展潛能，特別是在農業及生物科技方面的潛能，是參股亞洲生物能源的主要原因。

糧食供應樞紐

中國私募基金控股委任陳石義為代表進駐亞洲生物能源董事部，並於今日首次在股東大會亮相。擔任執行董事的陳石義在股東大會後向媒體表示，中國的食品消費正在成長，而全球糧食供應儲備卻正在下滑，但大馬及其他區域國家是良好的糧食供應樞紐，因此將續在區域中尋求投資機會。

於此同時，亞洲生物能源執行董事呂金龍針對該公司的展望表示，該公司預期業務能夠取得雙位數成長，因生物科技業務發展良好。他透露，一些政府機構正測試該公司的生物科技產品且取得良好的效果，該機構位於吉打州的稻米不僅成功抵抗病毒且收成獲得增長，這激勵該公司更積極地推廣該生物科技產品。

未來展望方面，他表示該公司依然專注於投資科技領域，並持續在中國與美國物色良好潛能的科技公司。

“事實上，我們已經與中國郵政媒體聯號公司簽署備忘錄以參與後者的投資活動，包括發展互動媒體及提供付賬服務的互動小站。”

“這是我們進軍中國市場的第一步，此後還會續在中國尋找投資機會。”

他也提及，與宜鼎機械（AT,0072,創業板工業產品組））實業是生物科技業務擴張計劃之一。

“我們將為宜鼎機械提供能夠增加收成及加速分解廢物的科技與設計，而他們將負責製造機器並行銷至適合的市場。”（星洲日報／財經）


放眼盈利双数增长 亚洲生化拟引中美科技

财经新闻 财经  2013-07-27 12:54
（吉隆坡26日讯）亚洲生化（AsiaBio，0150，创业板）主席拿督黄顺伟认为，在生物科技业务前景看俏下，希望今年可录得双位数的盈利增长。

黄顺伟在公司股东常年大会结束后向媒体表示，公司正积极在中国、美国和各地寻找引入新科技以拓展业务。

“我们最新的木料生产计划即将在中国启动，机械也会在未来数月内送到。”

上述计划是以棕油树干为原料来生产木料，而且公司也已找到了来自国外的客户。

“我们非常看好这项计划的前景，也预计这可为公司带来可观的收入。”

原料价格挑战

他续称：“目前，我们手中还有数项计划正在进行中，而且进度良好。截至今年首季，我们成功录得了230万令吉的净利。”

黄顺伟由此设下目标，希望2013年盈收达到双位数的增长。

不过，由于公司核心业务是科技研发，所以每项投资都会损耗盈收。

“每项投资都会导致我们的财务波动不稳，原料价格也是一个挑战。不过我们拥有强稳的客源和业务，所以这都不是大问题。”

出席股东大会后记者会的高层，包括了亚洲生化执行董事吕金龙和执行董事陈石义。

Biofutures交易额变动 将召开特大表决

针对亚洲生化与英国上市公司Biofutures国际股权交易数额变动一事，吕金龙表示，将于数月后召开股东特别大会，寻求股东批准有关数额变动。

亚洲生化去年杪献议以换股方式脱售旗下Platinum Nanochem私人有限公司股权予Biofutures国际，而亚洲生化可以126万1123英镑（587万3049令吉）或每股0.06英镑的代价，换取Biofutures国际1.05%股权。

不过，马交所在今年4月时发信予亚洲生化，称该公司是以每股0.07英镑，相等于685万1890令吉的价格，获得Biofutures国际的2101万8714股新普通股，因而要求公司寻求股东批准交易数额变动。

交易已经完成

吕金龙表示：“事实上，我们和Biofutures国际的交易已经完成，但我们还是需要召开特大，让股东表决交易数额变动一事。”

无论如何，他表示这并不会为公司带来影响。

“最坏的情况是股东反对，但我们就会退还多余的数额或股权。但是股权互换活动已经完成，所以不会带来显著影响。”[南洋网财经]

icy97

Notice of Interest Sub. S-hldr (29A)

ASIA BIOENERGY TECHNOLOGIES BERHAD

Particulars of Substantial Securities Holder

Name	The Goldman Sachs Group, Inc. ("TGSGI")
Address	Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, United States of America
NRIC/Passport No/Company No.	2923466
Nationality/Country of incorporation	United States of America
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	Goldman Sachs International ("GSI") Peterborough Court, 133 Fleet Street, London EC4A 2BB, United Kingdom

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	15/08/2013
No of securities	22,159,500
Circumstances by reason of which Securities Holder has interest	Indirect interest through open market acquisition of shares of Asia Bioenergy Technologies Berhad by GSI. GSI is a subsidiary of Goldman Sachs Holdings (U.K.), which is a subsidiary of Goldman Sachs Group Holdings (U.K.), which is in turn a subsidiary of Goldman Sachs (UK) L.L.C. TGSGI is the direct holding company of Goldman Sachs (UK) L.L.C. and the ultimate holding company of the other aforementioned entities.
Nature of interest	Indirect interest
Price Transacted ($$)
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	22,159,500
Indirect/deemed interest (%)	5.27
Date of notice	22/08/2013

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/07/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/07/2013	31/07/2012	31/07/2013	31/07/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	612	790	664	1,093
2	Profit/(loss) before tax	-1,377	-1,802	938	-1,793
3	Profit/(loss) for the period	-1,377	-1,802	938	-1,793
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,347	-1,787	994	-1,775
5	Basic earnings/(loss) per share (Subunit)	-0.32	-0.47	0.24	-0.46
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0598		0.0531